Navigation Links
Romark Announces Clinical Trial Results for New Influenza Drug Presented at IDSA Meeting 2011
Date:10/21/2011

Jason Haffizulla, Harvey Resnick, Aaron Hartman, Stefan Comhaire, Maria Carríon, Matthew Bardin. Presentation Number LB-35, Session 182a: Late Breaker Oral Abstracts - Clinical Virology and Treatment. Saturday, October 22, 2011, 6:30 PM.

About the US Clinical Trial

The clinical trial was conducted in 74 outpatient primary care centers throughout the United States during the 2010-2011 flu season.  624 patients, 12 to 65 years of age, with influenza symptoms were enrolled in the study within 48 hours of symptom onset and received treatment with 300 mg NTZ, 600 mg NTZ or placebo twice daily for 5 days.  Patients who received an influenza vaccine after August 1, 2010 and patients at risk of complications of influenza based upon CDC or IDSA criteria were excluded from participation in the trial. The study was designed according to FDA Guidance and consistent with prior clinical trials of Tamiflu® and Relenza®. The primary efficacy endpoint of the study was time from first dose to alleviation of symptoms (all symptoms absent or mild and remain so for 24 hours).  

Two hundred and fifty-seven (257) of the 624 patients enrolled in the study (41%) had laboratory confirmed influenza infection by RT-PCR or viral culture at baseline. Approximately half of the influenza-infected patients enrolled in the US clinical trial were infected with influenza A subtype H1N1 ("swine flu") with approximately 30% being infected with influenza B and 20% with influenza A subtype H3N2. The trial achieved its primary endpoint showing that influenza-infected patients treated with NT-300 administered 600 mg twice daily for five days experienced statistically significant reduction in time from beginning treatment to alleviation of flu symptoms compared to influenza-infected patients receiving the placebo (P=0.008). Median time to alleviation of symptoms was 95.5 hours for the 600 mg dose group compared to 109.1 hours for the 300 mg do
'/>"/>

SOURCE Romark Laboratories, L.C.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Raises $18 Million in Institutional Financing
3. Romark Laboratories Initiates Phase II Study of Nitazoxanide in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1
4. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at EASL 2008
5. Romark Laboratories Completes Enrollment in U.S. Phase II Study of Nitazoxanide for Chronic Hepatitis C Genotype 1 Non-Responders
6. Romark Initiates Clinical Trial of Alinia for Treatment of Influenza
7. NeuroFocus and New Scientist Magazine Apply Neuromarketing to Select Cover Design
8. Intercell and Romark Join Forces in Combining Therapies Against Hepatitis C
9. Romark and Intercell Join Forces in Combining Therapies Against Hepatitis C
10. Romark Announces Data Presented at AASLD Meeting 2010
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015  Mylan ... its shareholders have approved Mylan,s proposed acquisition of ... and the related issuance of Mylan ordinary shares ... of shareholders held today. The transaction received the ... general meeting. In addition, the transaction received support ...
(Date:8/28/2015)... 2015 The report "Eubiotics Market by Type (Probiotics, ... and Aquaculture), & by Region ( North America ... , and Rest of the World) - Global Trends and ... Eubiotics was valued at USD 4.62 Billion in 2014 and ... a CAGR of 7.4% from 2015 to 2020. ...
(Date:8/28/2015)... Massachusetts and LONDON , August ... approach seamlessly connects ... continuum improving outcomes and the ...  (NYSE: PHG AEX: PHIA) today announced its presence at  ... latest cardiology solutions, including Heart Model A.I. , EchoNavigator and ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4
... YORK , Aug. 2 Reportlinker.com announces that a new market research report is ... Hepatitis C Therapeutics ... http://www.reportlinker.com/p0236386/Hepatitis-C-Therapeutics-Market---Taiwan.html , ... This research service aims to provide an update on ...
... SHANGHAI , Aug. 2 /PRNewswire-Asia/ -- WuXi ... a leading research and development outsourcing company serving the,pharmaceutical, ... the United States , today announced its financial ... . , (Logo: http://photos.prnewswire.com/prnh/20040705/CNM002LOGO ...
Cached Medicine Technology:Hepatitis C Therapeutics Market - Taiwan 2Hepatitis C Therapeutics Market - Taiwan 3Hepatitis C Therapeutics Market - Taiwan 4Hepatitis C Therapeutics Market - Taiwan 5WuXi PharmaTech Announces Second-Quarter 2010 Results 2WuXi PharmaTech Announces Second-Quarter 2010 Results 3WuXi PharmaTech Announces Second-Quarter 2010 Results 4WuXi PharmaTech Announces Second-Quarter 2010 Results 5WuXi PharmaTech Announces Second-Quarter 2010 Results 6WuXi PharmaTech Announces Second-Quarter 2010 Results 7WuXi PharmaTech Announces Second-Quarter 2010 Results 8WuXi PharmaTech Announces Second-Quarter 2010 Results 9WuXi PharmaTech Announces Second-Quarter 2010 Results 10WuXi PharmaTech Announces Second-Quarter 2010 Results 11WuXi PharmaTech Announces Second-Quarter 2010 Results 12WuXi PharmaTech Announces Second-Quarter 2010 Results 13WuXi PharmaTech Announces Second-Quarter 2010 Results 14WuXi PharmaTech Announces Second-Quarter 2010 Results 15WuXi PharmaTech Announces Second-Quarter 2010 Results 16
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... On Saturday, ... Mesothelioma Applied Research Foundation (Meso Foundation) will present an educational program titled ... 7:00 PM and lasts through 9:30 PM (doors open at 6:45pm) at Calvary United ...
(Date:8/29/2015)... CA (PRWEB) , ... August 29, 2015 , ... Dr. ... a mission. His mission is to increase acceptance of the chiropractic field in ... medications that further debilitate them. Although Chiropractic was made available to the VA ...
(Date:8/29/2015)... ... August 29, 2015 , ... People ... pulmonary disease (including emphysema), or asthma, are at higher risk from wildfire smoke ... attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are also sensitive ...
(Date:8/28/2015)... ... August 29, 2015 , ... Rio Salado College joined nine educational ... as part of the EDUCAUSE - Next Generation Learning Challenges 2015 Breakthrough Models Incubator ... third Breakthrough Models Incubator hosted by EDUCAUSE and NGLC, which is designed ...
(Date:8/28/2015)... ... 2015 , ... The Kentucky State Department of Workforce Investment Commissioner Beth Kuhn ... applying for, they are unable to pass the initial drug test and therefore unable ... in order to be able to hire long-term, skilled talent. (1) Will Wesch, Director ...
Breaking Medicine News(10 mins):Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2Health News:The Patriot Project brings Chiropractic Care to the Armed Forces and their Families - Rapid Release Technology Joins the Effort to Recruit more Doctors to Pledge 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 2Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 3Health News:Rio Salado College Joins 9 Educational Leaders to Reinvent Higher Learning 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... for human malignant mesothelioma (MM) that will provide valuable ... directions for design of therapeutic strategies. The research, published ... Cell, may eventually lead to a substantially improved outlook ... is an aggressive cancer originating from the mesothelial lining ...
... who do not comply with treatment instructions for osteoporosis ... likely to suffer further fractures, which seriously affects their ... to provide support to these patients and address their ... guidelines drawn up, according to lead researcher Professor Cyrus ...
... University Medical Center say they may have figured out ... in women than in men. , Their study, appearing ... that poor sleep is associated with greater psychological distress ... of heart disease and type 2 diabetes. They ...
... VALLEY, Calif., March 10 VoIP-PAL.com,Inc. (Pink Sheets: ... pleased to report it has chosen the Carol ... first recipient. Four,dollars from each transaction exclusively through ... VoIP-PAL.com,s clients will additionally have the option to ...
... should be left on, then removed as a unit once ... During on-field treatment of young athletes with suspected neck injuries, ... initial stabilization and transport, and removed when the patient is ... "There was a clear hole in the on-the-field guidelines in ...
... making many diseases increasingly difficult--and sometimes impossible--to treat, ... the National Institute of Allergy and Infectious Diseases ... Extensively drug-resistant tuberculosis and invasive methicillin-resistant Staphylococcus aureus ... this problem that pose serious threats to domestic ...
Cached Medicine News:Health News:Mouse model for mesothelioma reproduces human disease 2Health News:Make or break time for osteoporosis treatment 2Health News:Poor sleep more dangerous for women 2Health News:Poor sleep more dangerous for women 3Health News:VoIP-PAL.com, Inc. (Pink Sheets: VPLM.PK - News) UPDATE: Announces First Award Recipient of TalkfortheCure(TM) Dollars 2Health News:New Guidelines Urged for Young Athletes' Neck Injuries 2Health News:Confronting the challenge of antimicrobial resistance 2Health News:Confronting the challenge of antimicrobial resistance 3
Super High Density, multi-frequency, convex array transducer for scanning during craniotomies. Same footprint as the UST-987-7.5 but with stronger penetration for deep cavernous tumors and other deep...
High resolution, multi-frequency, HST version of the UST-987-7.5. Provides even greater image detail, better resolution, and penetration....
... our High Penetration Steered Linear Peripheral Vascular ... to 8 MHz. It is our ... Detection with 4 different settings to optimize ... The high color and Doppler sensitivity of ...
... Super High Density, multi-frequency, linear ... "twist on the UST-5536, this ... it sweeps horizontally as well ... axis so that target lesions ...
Medicine Products: